(Information sent by the signatory company)
MUMBAI, India and GRANGEMOUTH, Scotland, December 19, 2023 /PRNewswire/ — Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO) and part of Piramal Pharma Ltd. (PPL) (NSE: PPLPHARMA) (BSE: 543635), today celebrated the opening of its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, United Kingdom.
Among the dignitaries taking part in the ceremony and ribbon cutting to formally commission the facility were Adrian Gillespie, chief executive of Scottish Enterprise. Representing Piramal were Nandini Piramal, Chairman of Piramal Pharma Limited; Peter DeYoung, CEO of Piramal Pharma Solutions; Hervé Berdou, COO of Piramal Pharma Solutions; Chris Leahy, senior vice president of finance, Piramal Pharma Solutions; and Francois Houbart, Managing Director and Head of Grangemouth Site, Piramal Pharma Solutions.
Piramal Pharma Solutions is a global leader in ADC development and manufacturing, with hundreds of payloads developed and over a thousand batches of ADCs manufactured. This expansion further enhances the site’s capacity by approximately seventy to eighty percent, allowing for the expansion of ADC’s commercial manufacturing lots. The capacity expansion, which was completed for commercialization within this fiscal year, features two new ADC manufacturing suites specifically designed to complement the existing three. The £45m investment was funded through a combination of government grants from Scottish Enterprise, bank loans, customer co-investment and internal accruals.
The primary beneficiaries of the expansion are Piramal’s customer base and the patients they serve, who are now further supported by the site’s enhanced capacity to deliver the full lifecycle of ADC development and manufacturing. This includes ADCelerate™, the company’s branded solution for the rapid early development of ADC drugs. This integrated offering combines monoclonal antibody (mAb) development, linker/payload, conjugation and sterile fill/finish into a single integrated program across four global Piramal sites, including Grangemouth. The approach simplifies development and manufacturing, speeding up the process by which new compounds can reach patients who need them. Programs like ADCelerate, along with Grangemouth’s highly skilled workforce, exemplify how Piramal delivers the best science to its clients and patients.
The site expansion also includes a dedicated customer experience center for customers visiting the site during development and/or manufacturing activities, along with new quality control laboratories, storage, office space and supporting utilities. The building, which used modular construction technology to accelerate its completion, has been designed to accommodate further expansion. Possible future enhancements may include a new sterile fill/finish assembly dedicated to ADCs and two additional large-scale manufacturing assemblies capable of handling larger batch sizes.
Peter DeYoung, CEO of Piramal Pharma Solutions, said: “The global ADC market is growing strongly, as is the portfolio in Grangemouth, requiring additional capacity to meet customer demand. This expansion allows us to serve a further growth and take on future projects. We see the market gravitating towards large-scale and commercial manufacturing, for which the new facility is well equipped. We have now doubled our ADC production capacity, strengthening our ability to serve customers for the entire life cycle of the drug.
Adrian Gillespie, CEO of Scottish Enterprise, commented: “Today’s opening marks the completion of Piramal’s welcome £45 million investment in Scotland’s life sciences sector, creating and safeguarding high quality jobs. We are pleased that “The company has chosen Scotland as the ideal location for its pioneering work in ADC, a new and growing area of medical innovation. We look forward to continuing and deepening our relationship with Piramal.”
Wellbeing Economy Secretary Neil Gray explained: “This £45m investment in pharmaceutical innovation helps build on Scotland’s strengths in health and life sciences, creating new jobs and opportunities as part of an and growing welfare system. It also adds to Grangemouth’s heritage as a manufacturing center for Scotland.”
Secretary Gray added: “Scotland’s National Innovation Strategy sets out our vision to become one of the world’s most innovative small nations over the next decade, working with partners to grow world-leading excellence in our priority areas.”
****
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) that offers end-to-end development and manufacturing solutions across the entire life cycle of medicines. We serve our customers through an integrated global network of facilities in North America, Europe and Asia. This allows us to offer a wide range of services including drug discovery solutions, pharmaceutical and process development services, clinical trial supplies, commercial supply of APIs and finished dosage forms. We also offer specialized services, such as the development and manufacturing of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics, including vaccines and gene therapies, made possible through Piramal Pharma Limited’s sister company, Yapan Bio Private Limited.
For more information, visit: www.piramalpharmasolutions.com | LinkedIn| Facebook | X (formerly Twitter)
About Piramal Pharma Limited
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, which sells over-the-counter products. Additionally, one of PPL’s associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the area. of ophthalmological therapy. Additionally, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: www.piramal.com/pharma | LinkedIn| Facebook | X (formerly Twitter)
About Scottish Enterprise
Scottish Enterprise (SE) is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. It supports businesses to innovate and scale to transform the Scottish economy by focusing on new market opportunities through targeted investment, innovation and internationalisation.
Follow us on X (formerly Twitter) and LinkedIn.
Photo – https://mma.prnewswire.com/media/2303655…Photo – https://mma.prnewswire.com/media/2303649…Photo – https://mma.prnewswire.com/media/ 2303651…Photo – https://mma.prnewswire.com/media/2303654…Photo – https://mma.prnewswire.com/media/2303652…Logo – https://mma.prnewswire. com/media/1726186…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/piramal-pharma-solutions-conmemora-la-apertura-de-su-expansion-de-fabricacion-de-adc-en-grangemouth-escocia-302018953.html
